Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Tempus, Active Motif, Immudex, Zymo Research, More

Tempus xG

Tempus has launched a new germline sequencing assay, xG, a 52-gene panel that specifically identifies genetic variants associated with hereditary cancer syndromes and inherited risk of cancer. The test is performed by BioReference Laboratories' subsidiary GeneDx and joins Tempus' existing suite of oncology-focused testing offerings, including tumor and liquid biopsy tests, HRD, and TO (tumor of unknown origin) assays.

Active Motif Hi-C Epigenetic Service

Active Motif has launched an end-to-end Hi-C service built on Arima Genomics' Hi-C kits. Hi-C is used by the research community and multiple large consortia such as ENCODE and 4D Nucleome to investigate how genome folding and misfolding impacts gene accessibility, regulation, and expression, and its impact on disease states. Under an agreement with Arima, Active is launching its Active Motif Epigenetic Service to serve academic, pharma, and clinical researchers.

Immudex dCode Dextramer (RiO) Reagents for BD Rhapsody System

Danish life sciences firm Immudex has launched dCode Dextramer (RiO) reagents for use with Becton Dickinson's BD Rhapsody single-cell analysis system. The new reagents are DNA-barcoded versions of the company's MHC Dextramer reagents, and are designed for the identification of many different T-cell specificities in the same sample. The technology directly detects disease-specific T cells based on TCR recognition and DNA barcode labels.

Zymo Research COVID-19 Variant Sequencing Service

Zymo Research has launched its COVID-19 Variant Sequencing Service. The workflow consists of sample collection from testing centers, automated RNA extraction using KingFisher Flex robotics, sequencing with Illumina's COVIDSeq NGS workflow including analysis with the Dragen COVIDSeq analysis pipeline, and reporting. The final report includes COVID-19 strain identification, genome sequencing coverage, confirmed mutations, consensus genome, and raw sequence files. Zymo uses its DNA/RNA Shield preservative to inactivate the SARS-CoV-2 virus and stabilize its RNA.

For more new products and services, please visit the New Products page on our website.